Pathophysiology of Hodgkin's disease: Functional and molecular aspects

被引:45
作者
Gruss, HJ
Kadin, ME
机构
[1] HARVARD UNIV, SCH MED, BOSTON, MA 02215 USA
[2] BETH ISRAEL DEACONESS MED CTR, BOSTON, MA USA
来源
BAILLIERES CLINICAL HAEMATOLOGY | 1996年 / 9卷 / 03期
关键词
D O I
10.1016/S0950-3536(96)80019-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Hodgkin's disease (HD) is characterized by the presence of the typical, clonal malignant Hodgkin and Reed-Sternberg (H-RS) cells in a hyperplastic background of normal reactive lymphocytes, plasma cells, histiocytes, neutrophils, eosinophils and stromal cells. The neoplastic nature of HD is based on aggressive clinical progression, presence of the proliferating and atypical H-RS cells, aneuploidy and cellular clonality. Immunophenotypical studies have demonstrated frequent expression of lymphoid 'activation markers' including CD15, CD25, CD30, CD40, CD54, CD70, CD71, CD80, CD86 and MHC class II and less frequent expression of T- or B-cell-associated antigens by the neoplastic H-RS cells. The clonality of H-RS cells is demonstrated by clonal EBV integration, clonal cytogenetic abnormalities including p53 mutations and clonal immunoglobulin rearrangements in some HD cases. There is involvement of diverse molecules with oncogenic potential, including presence of viruses (Epstein-Barr virus and human herpes virus-6) and/or oncogenes/tumour suppressor genes (bcl-2/bcl-x, p53/MDM-2, c-myc, c-fms, N-ras, lck). The histopathological presentation and characteristic clinical features of HD correlate with an unbalanced production of multiple cytokines and define HD as a tumour of cytokine-producing cells. The proportion of malignant H-RS cells to reactive cellular components and fibrosis is dependent on the production of particular cytokines and allows subtyping of HD cases. The combined use of immunohistochemical, biochemical and molecular techniques has thus allowed recognition that HD represents more than one clinico-pathological entity with different types of H-RS cells. The defined mechanism for the biological nature, origin and oncogenesis of H-RS cells remains not fully understood, but is susceptible to further analysis using modern technology.
引用
收藏
页码:417 / 446
页数:30
相关论文
共 127 条
[1]  
ANAGNOSTOPOULOS I, 1989, BLOOD, V74, P810
[2]  
ANASTASI J, 1987, AM J PATHOL, V128, P573
[3]   VIMENTIN EXPRESSION BY REED-STERNBERG CELLS IN HODGKINS-DISEASE [J].
ANGEL, CA ;
CULLEN, RA ;
PRINGLE, JH ;
LAUDER, I .
VIRCHOWS ARCHIV A-PATHOLOGICAL ANATOMY AND HISTOPATHOLOGY, 1992, 421 (01) :9-11
[4]   DECREASED EXPRESSION OF CELLULAR MARKERS IN EPSTEIN-BARR VIRUS-POSITIVE HODGKINS-DISEASE [J].
BAI, MC ;
JIWA, NM ;
HORSTMAN, A ;
VOS, W ;
KLUIN, PH ;
VANDERVALK, P ;
MULLINK, H ;
WALBOOMERS, JMM ;
MEIJER, CJLM .
JOURNAL OF PATHOLOGY, 1994, 174 (01) :49-55
[5]   MDM2 EXPRESSION IS INDUCED BY WILD TYPE-P53 ACTIVITY [J].
BARAK, Y ;
JUVEN, T ;
HAFFNER, R ;
OREN, M .
EMBO JOURNAL, 1993, 12 (02) :461-468
[6]   ABERRANT CYTOPLASMIC EXPRESSION OF PROLIFERATING CELL NUCLEAR ANTIGEN IN HODGKINS-DISEASE [J].
BENJAMIN, DR ;
GOWN, AM .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1991, 15 (08) :764-768
[7]   RESTIN - A NOVEL INTERMEDIATE FILAMENT-ASSOCIATED PROTEIN HIGHLY EXPRESSED IN THE REED-STERNBERG CELLS OF HODGKINS-DISEASE [J].
BILBE, G ;
DELABIE, J ;
BRUGGEN, J ;
RICHENER, H ;
ASSELBERGS, FAM ;
CERLETTI, N ;
SORG, C ;
ODINK, K ;
TARCSAY, L ;
WIESENDANGER, W ;
DEWOLFPEETERS, C ;
SHIPMAN, R .
EMBO JOURNAL, 1992, 11 (06) :2103-2113
[8]  
BOYLE MJ, 1993, BLOOD, V81, P468
[9]  
CABANILLAS F, 1988, BLOOD, V71, P1615
[10]   EXPRESSION OF FUNCTIONAL CD30 ANTIGEN ON REED-STERNBERG CELLS AND HODGKINS-DISEASE CELL-LINES [J].
CARBONE, A ;
GLOGHINI, A ;
GATTEI, V ;
ALDINUCCI, D ;
DEGAN, M ;
DEPAOLI, P ;
ZAGONEL, V ;
PINTO, A .
BLOOD, 1995, 85 (03) :780-789